New Triple-Threat treatment trial for tough esophageal cancer
Disease control
Recruiting now
This study is testing whether adding an experimental drug called KC1036 to standard immunotherapy and chemotherapy works better for people with advanced esophageal cancer that has returned or spread. It will involve 60 adults who haven't had prior treatment for their advanced dis…
Phase: PHASE2 • Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC